Cantor Fitzgerald set a $15.00 price objective on Progenics Pharmaceuticals (NASDAQ:PGNX) in a report published on Thursday. The brokerage currently has a buy rating on the biotechnology company’s stock.
A number of other research analysts also recently weighed in on the company. BidaskClub raised Progenics Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Thursday. ValuEngine lowered Progenics Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, January 16th. Finally, Zacks Investment Research lowered Progenics Pharmaceuticals from a buy rating to a hold rating in a report on Saturday, January 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Progenics Pharmaceuticals presently has an average rating of Buy and an average target price of $12.35.
Progenics Pharmaceuticals (NASDAQ PGNX) opened at $8.10 on Thursday. Progenics Pharmaceuticals has a 52 week low of $4.60 and a 52 week high of $11.72. The company has a debt-to-equity ratio of 0.74, a current ratio of 6.31 and a quick ratio of 6.31.
Institutional investors and hedge funds have recently modified their holdings of the business. Aperio Group LLC bought a new stake in Progenics Pharmaceuticals during the 3rd quarter worth approximately $118,000. Fox Run Management L.L.C. bought a new stake in Progenics Pharmaceuticals during the 4th quarter worth approximately $100,000. Metropolitan Life Insurance Co. NY bought a new stake in Progenics Pharmaceuticals during the 4th quarter worth approximately $101,000. Teacher Retirement System of Texas bought a new stake in Progenics Pharmaceuticals during the 4th quarter worth approximately $142,000. Finally, Municipal Employees Retirement System of Michigan increased its holdings in Progenics Pharmaceuticals by 58.7% during the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 26,350 shares of the biotechnology company’s stock worth $194,000 after purchasing an additional 9,750 shares in the last quarter. 86.51% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Markets Daily and is the property of of Markets Daily. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.themarketsdaily.com/2018/03/12/progenics-pharmaceuticals-pgnx-given-a-15-00-price-target-by-cantor-fitzgerald-analysts.html.
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.